EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

SGLT2 inhibitors: from glucose-lowering to cardiovascular benefits

Alberto Preda, Fabrizio Montecucco iD, Federico Carbone iD, Giovanni G Camici, Thomas F Lüscher, Simon Kraler iD, Luca Liberale iD

Cardiovascular Research · 30.04.2024 · 120 (5) · 443-460

DOI: 10.1093/cvr/cvae047 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cardiovascular Research, online erschienen am 08.03.2024. Verfasst von Alberto Preda und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Cardiology, IRCCS San Raffaele Hospital, Vita-Salute San Raffaele University, Milan, Italy. Hauptthemen laut MEDLINE: Sodium-Glucose Transporter 2 Inhibitors, Diabetes Mellitus, Type 2, Cardiovascular Diseases, Blood Glucose. Die Arbeit wurde bisher 199-mal zitiert (Crossref) und nennt 204 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ministry of University and Research, National Recovery and Resilience Plan.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

An increasing number of individuals are at high risk of type 2 diabetes (T2D) and its cardiovascular complications, including heart failure (HF), chronic kidney disease (CKD), and eventually premature death. The sodium-glucose co-transporter-2 (SGLT2) protein sits in the proximal tubule of human nephrons to regulate glucose reabsorption and its inhibition by gliflozins represents the cornerstone of contemporary T2D and HF management. Herein, we aim to provide an updated overview of the pleiotropy of gliflozins, provide mechanistic insights and delineate related cardiovascular (CV) benefits. By discussing contemporary evidence obtained in preclinical models and landmark randomized controlled trials, we move from bench to bedside across the broad spectrum of cardio- and cerebrovascular diseases. With landmark randomized controlled trials confirming a reduction in major adverse CV events (MACE; composite endpoint of CV death, non-fatal myocardial infarction, and non-fatal stroke), SGLT2 inhibitors strongly mitigate the risk for heart failure hospitalization in diabetics and non-diabetics alike while conferring renoprotection in specific patient populations. Along four major pathophysiological axes (i.e. at systemic, vascular, cardiac, and renal levels), we provide insights into the key mechanisms that may underlie their beneficial effects, including gliflozins’ role in the modulation of inflammation, oxidative stress, cellular energy metabolism, and housekeeping mechanisms. We also discuss how this drug class controls hyperglycaemia, ketogenesis, natriuresis, and hyperuricaemia, collectively contributing to their pleiotropic effects. Finally, evolving data in the setting of cerebrovascular diseases and arrhythmias are presented and potential implications for future research and clinical practice are comprehensively reviewed.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Sodium-Glucose Transporter 2 InhibitorsDiabetes Mellitus, Type 2Cardiovascular DiseasesBlood GlucoseHumansAnimalsTreatment OutcomeSodium-Glucose Transporter 2Risk AssessmentRisk FactorsCardiovascular SystemBiomarkers

Stichwörter der Autor:innen

SGLT2 inhibitorsautophagydiabetesendothelial functionheart failureinflammationmitochondriaoxidative stress

Substanzen

Sodium-Glucose Transporter 2 InhibitorsBlood GlucoseSodium-Glucose Transporter 2SLC5A2 protein, humanBiomarkers

Autor:innen und Institutionen

  • Department of Clinical Cardiology, IRCCS San Raffaele Hospital, Vita-Salute San Raffaele University, Milan, Italy.
  • First Clinic of Internal Medicine, Department of Internal Medicine, University of Genoa, 6 viale Benedetto XV, 16132 Genoa, Italy.
  • IRCCS Ospedale Policlinico San Martino Genoa-Italian Cardiovascular Network, Genoa, Italy.
  • Center for Molecular Cardiology, University of Zürich, Schlieren, Switzerland.
  • Department of Research and Education, University Hospital Zurich, Zurich, Switzerland.
  • Royal Brompton and Harefield Hospitals and Imperial College and King's College, London, United Kingdom.

ORCID-Profile: Fabrizio Montecucco, Federico Carbone, Simon Kraler, Luca Liberale

Förderung

  • Ministry of University and Research
  • National Recovery and Resilience Plan

Zitieren

APA

Preda, A., Montecucco, F., Carbone, F., Camici, G. G., Lüscher, T. F., Kraler, S., & Liberale, L. (2024). SGLT2 inhibitors: from glucose-lowering to cardiovascular benefits. Cardiovascular Research, 120(5), 443-460. https://doi.org/10.1093/cvr/cvae047

Vancouver

Preda A, Montecucco F, Carbone F, Camici GG, Lüscher TF, Kraler S, et al. SGLT2 inhibitors: from glucose-lowering to cardiovascular benefits. Cardiovascular Research. 2024;120(5):443-460. doi:10.1093/cvr/cvae047

BibTeX
@article{Preda2024,
  author = {Preda, Alberto and Montecucco, Fabrizio and Carbone, Federico and Camici, Giovanni G and Lüscher, Thomas F and Kraler, Simon and Liberale, Luca},
  title = {SGLT2 inhibitors: from glucose-lowering to cardiovascular benefits},
  journal = {Cardiovascular Research},
  year = {2024},
  volume = {120},
  number = {5},
  pages = {443--460},
  doi = {10.1093/cvr/cvae047}
}
Kostenlos starten →